^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) + Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Published date:
07/04/2022
Excerpt:
COSMIC-312 is an open-label, randomised, phase 3 trial that enrolled patients aged 18 years or older with advanced hepatocellular carcinoma...Median progression-free survival was 6·8 months (99% CI 5·6–8·3) in the combination treatment group versus 4·2 months (2·8–7·0) in the sorafenib group (hazard ratio [HR] 0·63, 99% CI 0·44–0·91, p=0·0012).
DOI:
https://doi.org/10.1016/S1470-2045(22)00326-6
Trial ID:
